Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment
- PMID: 20602173
- DOI: 10.1007/s11102-010-0238-3
Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment
Abstract
In thyrotoxicosis GH responses to stimuli are diminished and the hypothalamic-pituitary-adrenal axis is hyperactive. There are no data on ghrelin or GHRP-6-induced GH, ACTH and cortisol release in treated hyperthyroidism. We, therefore, evaluated these responses in 10 thyrotoxic patients before treatment and in 7 of them after treatment. GHRH-induced GH release was also studied. Peak GH (μg/L; mean ± SE) values after ghrelin (22.6 ± 3.9), GHRP-6 (13.8 ± 2.3) and GHRH (4.9 ± 0.9) were lower in hyperthyroidism before treatment compared to controls (ghrelin: 67.6 ± 19.3; GHRP-6: 25.4 ± 2.7; GHRH: 12.2 ± 2.8) and did not change after 6 months of euthyroidism (ghrelin: 32.7 ± 4.7; GHRP-6: 15.6 ± 3.6; GHRH: 7.4 ± 2.3), although GH responses to all peptides increased in ~50% of the patients. In thyrotoxicosis before treatment ACTH response to ghrelin was two fold higher (107.4 ± 26.3) than those of controls (54.9 ± 10.3), although not significantly. ACTH response to GHRP-6 was similar in both groups (hyperthyroid: 44.7 ± 9.0; controls: 31.3 ± 7.9). There was a trend to a decreased ACTH response to ghrelin after 3 months of euthyroidism (35.6 ± 5.3; P = 0.052), but after 6 months this decrease was non-significant (50.7 ± 14.0). After 3 months ACTH response to GHRP-6 decreased significantly (20.4 ± 4.2), with no further changes. In hyperthyroidism before treatment, peak cortisol (μg/dL) responses to ghrelin (18.2 ± 1.2) and GHRP-6 (15.9 ± 1.4) were comparable to controls (ghrelin: 16.4 ± 1.6; GHRP-6: 13.5 ± 0.9) and no changes were seen after treatment. Our results suggest that the pathways of GH release after ghrelin/GHRP-6 and GHRH are similarly affected by thyroid hormone excess and hypothalamic mechanisms of ACTH release modulated by ghrelin/GHSs may be activated in this situation.
Similar articles
-
Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.Pituitary. 2006;9(2):101-7. doi: 10.1007/s11102-006-9149-8. Pituitary. 2006. PMID: 16832586 Clinical Trial.
-
Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus.Metabolism. 2010 Oct;59(10):1536-42. doi: 10.1016/j.metabol.2010.01.021. Epub 2010 Mar 1. Metabolism. 2010. PMID: 20189610 Clinical Trial.
-
Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism.Mol Cell Endocrinol. 2002 Nov 29;197(1-2):97-103. doi: 10.1016/s0303-7207(02)00293-9. Mol Cell Endocrinol. 2002. PMID: 12431802 Clinical Trial.
-
Growth hormone-releasing peptides: clinical and basic aspects.Horm Res. 1996;46(4-5):155-9. doi: 10.1159/000185015. Horm Res. 1996. PMID: 8950613 Review.
-
Biologic activities of growth hormone secretagogues in humans.Endocrine. 2001 Feb;14(1):87-93. doi: 10.1385/ENDO:14:1:087. Endocrine. 2001. PMID: 11322506 Review.
Cited by
-
Clinical review: The human experience with ghrelin administration.J Clin Endocrinol Metab. 2013 May;98(5):1826-37. doi: 10.1210/jc.2012-4247. Epub 2013 Mar 26. J Clin Endocrinol Metab. 2013. PMID: 23533240 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources